Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors

• Published in: Peptides (New York, N.Y. : 1980) Vol. 62; pp. 164 - 175
• Main Authors: Sitticharoon, Chantacha, Nway, Nay Chi, Chatree, Saimai, Churintaraphan, Malika, Boonpuan, Peerada, Maikaew, Pailin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2014
• Subjects: Adiponectin; Adiponectin - biosynthesis; Adiponectin - blood; Adiponectin - genetics; Adult; Bismaleimides; Body Mass Index; Circumferences; Correlation; Cytokines - biosynthesis; Cytokines - blood; Cytokines - genetics; Gain; Gene expression; Gene Expression Regulation; GPI-Linked Proteins - biosynthesis; GPI-Linked Proteins - blood; GPI-Linked Proteins - genetics; Humans; Insulin; Insulin - blood; Insulin Resistance - genetics; Intra-Abdominal Fat - metabolism; Lectins - biosynthesis; Lectins - blood; Lectins - genetics; Mathematical models; Middle Aged; Nicotinamide Phosphoribosyltransferase - biosynthesis; Nicotinamide Phosphoribosyltransferase - blood; Nicotinamide Phosphoribosyltransferase - genetics; Obesity; Obesity - blood; Obesity - pathology; Obesity - physiopathology; Omentin; Peptide YY - blood; QUICKI; Serums; Subcutaneous Fat - metabolism; Visfatin; Obesity; QUICKI; Visfatin; Omentin; Adiponectin
• ISSN: 0196-9781; 1873-5169
• DOI: 10.1016/j.peptides.2014.10.006

•Adiponectin expression and serum levels were the highest of the adipokines.•QUICKI could be used to predict serum adiponectin and omentin-1.•Weight gain could be used to predict serum visfatin, and omentin-1.•PYY correlated positively with subcutaneous but negatively with visceral visfatin.•Expression of the three adipokines was linked in each type of fat tissue. Adiponectin, visfatin, and omentin are adipokines involved in insulin sensitivity. This study aimed to determine interactions between these adipokines in subcutaneous and visceral fat and in serum, and their associations with clinical factors. Adiponectin was present at the highest levels in subcutaneous and visceral fat and serum. Subcutaneous adiponectin showed positive correlations with serum adiponectin and the quantitative insulin sensitivity check index (QUICKI). Serum adiponectin correlated positively with QUICKI and serum omentin-1 but negatively with body weight, BMI, and homeostasis model assessment of insulin resistance (HOMA-IR). Subcutaneous omentin correlated positively with QUICKI but negatively with waist and hip circumferences. Serum omentin-1 correlated positively with QUICKI but negatively with body weight, BMI, waist and hip circumferences, weight gain, and HOMA-IR. Serum visfatin correlated positively with serum omentin-1 and negatively with weight gain. Serum peptide YY (PYY) levels were correlated positively with subcutaneous visfatin but negatively with visceral visfatin. Positive correlations were observed between subcutaneous expression of adiponectin, visfatin, and omentin and visceral expression of these genes. Multiple linear regression analysis showed that serum adiponectin was associated with BMI and QUICKI. Serum omentin-1 could be predicted from BMI, QUICKI, and weight gain. Weight gain, serum adiponectin, omentin-1, and DBP could be used to predict serum visfatin. In conclusion, adiponectin and omentin from subcutaneous fat displayed correlations with decreased obesity and increased insulin sensitivity while visfatin showed an association with serum PYY and weight gain. The expressions of these adipokines were correlated within each type of fat but not between different fat depots.